DLIs are frequently used following haematopoietic SCT (HSCT) in patients with risk of relapse but data on GVHD following DLI are scarce. We report on 68 patients who received DLI following HSCT. Most patients developed GVHD following DLI (71%), which was acute in 22 patients (32%) almost half of whom had grade III-IV acute GVHD (aGVHD). Thirty patients (44%) developed cGVHD which followed aGVHD in four patients and was graded severe in nine patients. Corticosteroids were the most common first-line therapy for both acute and chronic GVHD. A wide range of second/third-line agents included cyclosporin, mycophenolate, tacrolimus, imatinib, infliximab and ECP. Relapse of initial malignancy occurred in 37%. Relapse was significantly less frequent in those receiving pre-emptive DLI. Relapse rates were also lower in those with GVHD (31%) than those without GVHD (50%), but this did not reach statistical significance. At 55 months post DLI, 34% of patients had died most commonly from relapse and 22% had on-going GVHD. Although GVHD was an important cause of morbidity post DLI (71%), only 6% died from GVHD. Although most patients develop GVHD post DLI and may require consecutive therapies, mortality from GVHD is infrequent. DLI remains an important option for relapse post transplant and manipulation of the GVT effect needs to be optimised to induce remission without morbidity from GVHD.
INTRODUCTION
DLI is the only form of adoptive immunotherapy that is in widespread use following haematopoietic SCT (HSCT) in patients with either mixed donor chimerism (pre-emptive) or relapse (therapeutic) to harness the graft-versus-tumour (GVT) effect. The first report of DLI leading to remission of disease following relapse after HSCT was in a patient with CML in 1990. 1 Prior to DLI, patients relapsing post HSCT would likely succumb to their disease and a few would receive a second transplant. Following success in CML, DLI was then utilised for other haematological malignancies such as acute leukaemia and myeloma. [2] [3] [4] [5] [6] The GVT effect, which is responsible for enabling sustained remission, is also responsible for the most frequent toxicity, GVHD. For this reason, significant pre-existing GVHD is considered a relative contraindication to DLI. There are limited data on the characteristics of GVHD post DLI or response to therapy. The aim of this study was to perform a multicentre study to investigate the type, severity, treatment and response rates of GVHD and DLI schedule.
MATERIALS AND METHODS
Consecutive patients receiving DLI after HSCT at five UK transplantation centres (Nottingham University Hospitals NHS Trust, Manchester Royal Infirmary, The Royal Marsden, London, King's College Hospital, London, University Hospital Birmingham NHS Trust, Birmingham) between 2005 and 2012 were identified from hospital databases. All patients consented to the collection of anonymised data in accordance with the Declaration of Helsinki. All patients gave informed consent for the administration of DLI as per institutional protocols in keeping with the human tissue act. Data were collected retrospectively and included diagnosis, date of transplant, dates and doses of DLI, date of onset of acute (aGVHD) and chronic GVHD (cGVHD), and characteristics of GVHD including organ involvement and staging. Severity of aGVHD was recorded using revised Glucksberg criteria 7, 8 and cGVHD according to NIH Criteria. 9, 10 Initial treatment of aGVHD was documented and subsequent aGVHD treatments were recorded as second, third or fourth line therapies. Treatments for cGVHD were also documented. Treatment responses were recorded from clinical notes and documented as CR, PR, stable disease or progressive disease. 11 CR was defined as resolution of all organ involvement. PR was defined as a greater than 50% response in organ involvement, but less than a CR. Stable disease was defined as stable organ involvement, despite the tapering of other immunosuppressive agents by at least 50% of the dosage and progressive disease as worsening of GVHD and the inability to taper other medications.
11
Follow-up in months was determined from date of DLI. Current status of those alive was recorded to include relapse of initial malignancy and/or evidence GVHD. Deaths and cause of death were documented. Follow-up was taken from date of first DLI. Any patients lost to follow-up were contacted via their general practitioner to ascertain current status.
Because of relatively small numbers, all categorical variables were tested for association with outcome variables (relapse, remission or deaths) using Fisher's exact test.
(n = 11), Manchester Royal Infirmary (n = 10) and The Royal Marsden (n = 10). Haematological malignancies were AML in 26, myelodysplastic syndrome in 12, CLL in 8, CML in 7, myeloma in 5, non-Hodgkin's lymphoma in 4, ALL in 2 and other in 4 (Hodgkin's disease in 1, mantle cell lymphoma in 1, follicular lymphoma in 1 and T-prolymphocytic leukaemia). Table 1 /kg). The reason cited for DLI was: pre-emptive (mixed chimerism) in 27, therapeutic in 40 patients (relapse in 32, molecular relapse in 5, and cytogenetic abnormality in 3) and consolidation in 1.
Acute GVHD Twenty-two patients developed aGVHD (32%). The median dose of first DLI was 1 × 10 6 /kg in both those developing aGVHD and those without aGVHD. The median time between first DLI dose and development of aGVHD was 1 month (mean 2, range 1-4 months). Organ involvement included skin in 18 (82%), liver in 9 (41%) and gut in 9 (41%). Thirteen patients (59%) patients had single organ involvement (skin only n = 11, liver only n = 2). Multi-organ involvement was present in nine patients (41%) and organ involvement is detailed in Table 2 . Four patients (18%) had revised Glucksberg grade I, eight (36%) grade II, five (23%) grade III and five (23%) grade IV ( Table 2) . Forty three patients (63%) received T-cell-depleted SCT. Of these,13 patients (30%) developed aGVHD compared with 9/25 patients (36%) developing aGVHD in those receiving non-T-celldepleted SCT. There was no statistical difference in those developing aGVHD who received T-cell-depleted versus T-cellreplete transplants (P = 0.85).
First-line treatment was corticosteroids in all 22 patients: oral prednisolone in 11 patients (dose 20-60 mg), methylprednisolone in 7 (2 mg/kg), topical corticosteroids in 3 (potent strength) and budesonide in 1. Nine patients (41%) had CR to first-line therapy defined as no evidence of aGVHD in any organ and this included two of four patients with grade I aGVHD, four of eight with grade II, two of five with grade III and one of five with grade IV aGVHD. Three (14%) patients had a PR in aGVHD and did not require any further systemic therapy for aGVHD but one out of three patients developed cGVHD.
Eight patients had progressive aGVHD. One died and seven had worsening aGVHD necessitating further systemic therapy. Secondline treatment was ECP n = 3, cyclosporin and mycophenolate mofetil n = 2, tacrolimus n = 1 and mycophenolate mofetil n = 1 and cyclosporin n = 1. Second-line treatment response was CR n = 3, relapse of malignancy n = 1, mild cGVHD n = 1 and progressive aGVHD n = 3 (one died). Third-line therapy was received in three patients (ECP n = 1 with a PR, daclizumab and infliximab n = 1 with progressive disease and death, MTX n = 1 with progressive disease and death). Of the four patients who 
Abbreviations: MDS = myelodysplastic syndrome; NHL = non-Hodgkin's lymphoma. GVHD following DLI JJ Scarisbrick et al progressed to cGVHD, one died from GVHD, one is alive but had relapse of the original malignancy and two are living in remission with cGVHD. Overall, 11 patients with aGVHD died (50%). The most common cause of death in this group was relapse in six patients (27%). Two (9%) died from aGVHD grade III-IV and one with grade III aGVHD that had subsequently progressed to cGVHD. Two died from pneumonia without significant GVHD. Table 3 shows outcome in patients who developed aGVHD compared with those with cGVHD or no GVHD. There was no statistical difference in deaths in those with aGVHD compared with those without GVHD (P = 0.5).
Chronic GVHD Twenty-six patients (38%) developed cGVHD without evidence of aGVHD. A further four developed cGVHD after acute and these patients are discussed above and not included here. The mean time between first DLI doses and development of cGVHD was 5.7 months (median 4, range 3-28 months). Organ involvement included skin in 19 patients (73%), oral involvement in 15 (58%), liver in 9 (35%), eye in 6 (23%), gut in 4 (15%) and lung in 2 patients. Nine patients (35%) had single organ involvement (skin only in six, oral in two, eye in one). In 11 patients (42%), two organs were involved. These organs were most commonly skin and oral. Six patients had more than two organs involved. Details of organ involvement are shown in Table 4 . Severity of cGVHD was measured using NIH criteria 9, 10 and classified as mild in 6, moderate in 11 and severe in 9 patients (Table 4) .
Median time from HSCT to DLI was 15 months (range 5-36 months) in those without GVHD and also 15 months (range 2-73 months) in those developing cGVHD.
There was no statistical difference between those developing aGVHD who received T-cell-depleted versus non-T-cell-depleted transplants (P = 0.78). Forty-three patients (63%) received T-celldepleted SCT. Of these 43 patients, 15 (35%) developed cGVHD compared with 11/25 (44%) in those receiving non-T-celldepleted SCT.
First-line treatment for cGVHD was topical corticosteroids in nine patients (35%). Fifteen patients (58%) received oral prednisolone. Eleven patients received prednisolone alone. The remaining patients received combination immunosuppressive therapy with the addition of ciclosporin in two, tacrolimus in one and mycophenolate in one patient. One patient had mycophenolate and one rituximab. The first treatment response was CR in 16 patients (62%). Progressive cGVHD despite first-line therapy occurred in nine patients (35%), one of whom died of cGVHD and another died from relapse of their initial malignancy. Second-line treatment for the eight survivors with progressive cGVHD was ECP in four, mycophenolate in three, imatinib in one and infliximab in one. Second-line treatment response was CR in one and PR in six patients, and one patient had relapse of their malignancy. Third-line therapy was given in four of six patients with on-going cGVHD and included ECP in two and mycophenolate in two. One patient had a CR and three had a PR. One patient had a fourth-line treatment with ECP with a PR.
Seven patients in this cohort died but only one died from cGVHD. This patient was the only patient with lung involvement and had severe cGVHD. Five patients died from relapse and one had a ruptured abdominal aortic aneurysm. Of those dying from relapse, one had mild, two moderate and two severe cGVHD (Table 4 ).
Response to DLI Full donor chimerism (495%) was achieved in 46 of 67 patients (69%). A higher rate of full donor chimerism occurred in those receiving DLI for mixed chimerism in 24 of 27 patients (89%) after a median of one dose of DLI. Twenty-two of 40 patients (55%) receiving DLI therapeutically achieved full chimerism after a median of two DLI doses.
Relapse of primary malignancy Twenty-five of 67 patients (37%) had recurrence of their primary malignancy post DLI and 16 died from relapsed disease (24%). The highest rate of relapse was seen in those without GVHD occurring in 10 out of 20 patients (50%), but this was not statistically significant (P = 0.29). Eight out of 22 (36%) patients with aGVHD developed relapse during follow-up and 7/26 (27%) with cGVHD (Table 1) . Deaths from relapse occurred in 16 patients (24%) overall and deaths occurred in both those with and without GVHD at similar rates (23% died from relapse with GVHD compared with 25% without GVHD P = 0.879). The rates of relapse associated with initial diagnosis are shown in Table 1 . Rates of relapse were lower in those receiving pre-emptive DLI in 3/27 patients (11%) compared with 22/41 (54%) receiving therapeutic DLI (P o0.001).
Remission Thirty-six patients (53%) are currently in remission. This includes 11 patients who never experienced GVHD. On comparing the cohort without GVHD with those with GVHD, a similar of number patients achieved remission~50% (P = 0.13). The highest rates of remission were in the cGVHD cohort where 17 patients (65%) are currently in remission although 12 patients have on-going cGVHD, which is severe in 6.
Outcome
The mean follow-up from first DLI was 55 months (median 47, range 5-94). Twenty-three patients (34%) died post DLI during study follow-up. Cause of death was cited as relapse of malignancy in 16 (24%), GVHD in 4 patients (6%) and other in 3 patients (4%). Four patients had GVHD cited as the cause of death (three as aGVHD and one cGVHD). Three patients died from other causes (ruptured abdominal aortic aneurysm, pneumocystis pneumonia and pneumonia unspecified) and none of these patients had significant GVHD at time of death). There was no significant difference in death rates in those with or without GVHD (P = 0.51). Eleven of 20 (55%) patients without GVHD are alive in remission compared with only 8 of 22 (36%) with aGVHD of whom 2 have cGVHD but 17/26 (65%) with cGVHD are alive in remission although 12 have cGVHD which is severe in 6 (Table 3) . GVHD prior to DLI was seen in five patients. This had resolved at time of DLI and all of whom subsequently developed GVHD, but there was no mortality from GVHD in this group.
Comparing outcome in those who received matched related versus unrelated donor transplants found that, of the 39 patients who received matched related donor transplants, 12 (31%) developed aGVHD and a further 12 (31%) had cGVHD without preceding acute. The remaining 15 did not develop GVHD (38%). Of the 29 patients who received unrelated donor transplants, 10 (34%) developed acute and a further 14 (48%) had cGVHD without preceding acute. The remaining five patients (17%) had no documented evidence of GVHD. No significant difference was shown in the rate of GVHD between those receiving matched related or unrelated donor transplants (P = 0.34). Of those 39 patients who received a matched related transplant, 13 died (33%) including 11 (28%) from relapse, 1 from aGVHD (3%) and 1 from pneumonia. Of those 29 patients receiving unmatched transplants, 10 died (34%) including 5 (17%) from relapse, 3 (10%) from GVHD, 1 from pneumonia and 1 from ruptured aortic aneurysm. No significant difference was noted in the number of deaths between those receiving matched or unmatched transplants (P = 0.56).
Outcomes were compared in patients who received DLI preemptively with those who received DLI therapeutically. Twentyseven patients received pre-emptive DLI and 10 patients (37%) developed aGVHD and 5 (19%) cGVHD compared with 12 (29%) developing aGVHD and 21 patients (51%) developing cGVHD following DLI for relapse or consolidation. Rates of GVHD were significantly lower in those receiving pre-emptive DLI than therapeutic (P = 0.03). Of those 27 who received pre-emptive DLI, 7 died (26%); 3 from relapse, 2 from GVHD (1 acute and 1 chronic) and 2 from pneumonia. Sixteen patients (39%) died after receiving DLI for relapse. There was a lower rate of relapse deaths in those receiving pre-emptive DLI (P = 0.01) but no significant difference in OS between the pre-emptive or therapeutic regimes (P = 0.31).
DISCUSSION
The use of DLI either pre-emptively or therapeutically is useful in post-transplant graft manipulation to enhance the GVT effect, but this is offset by the induction of GVHD. Little is known regarding the best approach to DLI to improve disease responses and minimise toxicity from GVHD, and responses to DLI are unpredictable. 12 Efforts to improve DLI by only infusing specific cytotoxic T lymphocyte clones, or CD8 depletion 13 or the use of suicide genes such as the HSV thymidine kinase have been studied to reduce donor T-cell expansion and GVHD.
14 However, none have been universally adopted and despite the advent of new therapies such as vaccination strategies and adoptive cell transfer to treat relapse post HSCT, DLI remains an important means of treating relapse post HSCT. 15, 16 Prophylactic DLI is being trialled post HSCT in those at high risk of relapse but may be limited by severe GVHD. 17, 18 In this study, 40% of patients received DLI pre-emptively.
DLI has been shown to be especially effective in CML, 15 but only 10% of our cohort had CML. In Europe and US, AML is the most common malignancy treated with HSCT accounting for 32% and 37%, respectively, and was the most frequent malignancy receiving DLI in this study with 38% of patients having AML. Within this group, 58% were alive at a median follow-up of 55 months and 54% were alive in remission suggesting this is a useful treatment for post-HSCT relapse. Previous studies have shown DLI to be effective in AML although reported remission rates are low (15-20%) . 15 A recent report detailing 39 studies of patients receiving DLI found CRs overall in 27% (range 16-40%) Single organ involvement with highest responses in relapsed CLL (55%) and non-Hodgkin's lymphoma (52%) compared with 26% in multiple myeloma and 37% in Hodgkin's lymphoma. 19 Our study showed remissions in 53% ranging from 25 to 67% according to malignancy (Table 1) . However, 40% of our cohort received pre-emptive DLI, hence a direct comparison cannot be made. In our study, the relapse rates were significantly lower in those receiving DLI pre-emptively at 11%, compared with 54% receiving therapeutic DLI (P o0.001). However, OS in those receiving pre-emptive DLI compared with therapeutic was not improved.
GVHD following DLI was frequent in our cohort occurring in 71%; 32% had aGVHD documented and 38% cGVHD. Those receiving DLI pre-emptively had a lower rate of GVHD (56%) than those receiving therapeutic DLI (80%; P = 0.03). This may reflect fewer DLI doses received by the pre-emptive group. No other specific risk factors for the development of GVHD following DLI were identified in this paper including DLI dose, which was dictated by the donor type (related versus unrelated), time from transplant to DLI, history of prior GVHD, donor type or T-cell depletion. This is likely due to the relatively small numbers and diverse indications and types of transplant. MacKinnon et al. 5 previously found escalating cell doses to be a successful strategy to separate GVHD and GVL.
Although GVHD was frequent following DLI (71%), deaths from GVHD were rare with only 6% of patient's deaths attributable to GVHD. An earlier review of the published literature reported a similar incidence of 40-60% aGVHD and 33-61% cGVHD with 6-11% of deaths following DLI related to GVHD. 20 In the majority of patients developing GVHD after DLI, successful treatment may be achieved with increased immunosuppression. Of the patients, 39% received second-line therapy for GVHD, most commonly ECP; 21% received a third-line therapy.
The features of aGVHD following DLI were similar to those occurring after HSCT. aGVHD typically developed 1 month after initial dose of DLI. The most common organ involved was skin affecting 82% with aGVHD; 41% had liver and 41% had gut involvement, which is similar to aGVHD post HSCT. A high rate of liver GVHD with a hepatitic pattern of abnormal liver function tests has been reported with DLI but this was not found in our cohort. [20] [21] [22] Grade III-IV aGVHD was reported in 15% of the cohort. All patients were initially treated with corticosteroids and 55% had a good response, but 36% had progressive aGVHD necessitating further treatment. Four patients with aGVHD developed cGVHD. A third of patients developing aGVHD had relapse of their primary malignancy and a quarter died from relapse, which were similar to rates in those not developing GVHD. This suggests that in our cohort, aGVHD did not convey any protection against relapse.
Features of cGVHD post DLI were also similar to cGVHD following HSCT typically developing 6 months following the initial dose of DLI, but was also reported as a late feature more that 2 years post DLI. The most frequent organs involved included skin in 73%, followed by oral involvement in 58%. The majority had GVHD in one to two organs (35% had one and 42% two organs involved). A third developed severe GVHD. First-line treatment for cGVHD was corticosteroids and a third required only topical therapy. A high number of patients (62%) had a CR to first-line therapy.
Those with cGVHD had a lower rate of relapse (27%) than those without GVHD (50%), but this did not reach statistical significance, which may reflect the relatively small cohort size. GVHD offers some protection against relapse of malignancy (GVT effect), but although relapse of the original malignancy was highest in those without GVHD, mortality from relapse was similar in those with and without GVHD, P = 0.879 (Table 3) . Relapse rates and deaths from relapse were significantly lower in those receiving preemptive DLI compared with therapeutic (P o 0.001, P = 0.01) but OS following DLI was similar (P = 0.31).
Extensive cGHVD but not aGVHD has previously been found to decrease relapse and increase the probability of survival and the protective effect of aGVHD was assumed to be negated by the corticosteroids and immunosuppressive treatments. 23 GVHD and GVT are linked by a number of shared biological pathways and there is evidence that they may occur independently. 24 In this study, 55% of patients had remission without developing GVHD supporting the assumption that the GVT effect may predominate without causing pathological GVHD.
In this study, with a mean follow-up of 55 months following initial dose of DLI, 66% of patients were alive. Although relapse was less frequent in those receiving pre-emptive DLI, compared with therapeutic DLI, OS was similar. The most common cause of death in the cohort was relapse and although GVHD developed in over two-thirds of patients, mortality from GVHD was infrequent. cGVHD but not aGVHD was associated with a decreased risk of relapse. From this study, aGVHD is a negative factor as it prevents further DLI from being given but does not appear to prevent relapse. Exploring therapies to prevent aGVHD may improve outcome following DLI. This study supports DLI as a successful therapy with 69% of all patients achieving full chimerism with 53% currently alive in remission. Improving manipulation of the GVT effect without promoting GVHD may improve outcome.
